CompassX Newsletter May - June 2018Read Magazine
CompassX Group, A Health Management Consulting Firm, Released A Comprehensive Study About The Rise In Drug Discovery Costs And Why This Is Good News For Consumers
Managing Director Kyle J. Heppenstall, has released his latest position paper and, according to the paper, drug development costs have risen 145% since 2003, but in a contrarian statement that might surprise many he states, “Consumers are getting a good deal.”Read Article
CompassX Consulting Reveals 3 Steps to Aid the FDA Drug Approval Process—Is $4 Trillion at Stake?
CompassX Managing Partner, Kyle J. Heppenstall, recently spoke about deploying improvements to the FDA’s drug approval process which are getting a significant amount of attention. His presentation analyzed the recent improvements made by the FDA’s Center for Drug Evaluation and Research (CDER), but also reveals that further improvements can be achieved. According to Heppenstall, “This doesn’t mean the FDA can stop moving forward. A formal operational excellence study can produce significant return on investment for the FDA and the health of U.S. citizens.”Read Article
Supreme Court Decisions on Patents Could Mean Trouble Ahead for Biotech Innovation, Says Health Sector Consultant, Kyle J. Heppenstall
Newly issued guidance by the Supreme Court has the potential to reshape the landscape of biologic drug and product commercialization, says Kyle J. Heppenstall, Managing Director of CompassX Consulting, a consultancy focused on architecting and executing strategies for healthcare and regulated industries.Read Article